Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, James Izanec et al.|The Lancet|2022Cited by 295
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s DiseaseSatish Keshav, Tomáš Vaňásek, Yaron Niv et al.|PLoS ONE|2013Cited by 134